Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...

AstraZeneca's three-drug inhaler Breztri has shown efficacy for uncontrolled asthma in a pair of trials that could extend its label beyond COPD. The importance of biosimilars only continues to ...

AstraZeneca's 'smoker's Lung' Therapy Meets Main Goals Of Late-stage Asthma Trials AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage ...